A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301). Background: Response rates (55-65%) with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results